UroToday.com· @urotoday · X·· 2 days agoScore70
Body
Perioperative Pembrolizumab or PBO + Neoadjuvant Cisplatin and Gemcitabine in Participants with Muscle-Invasive #BladderCancer #MIBC: The Double-Blind, Phase 3 KEYNOTE-866 Study. Presented by Jens Bedke, MD. #ESMO26 written coverage by @chavarriagaj > https://bit.ly/4epWdbe #Immunotherapy @myESMO
420 views · 5 likes · 2 reposts · 0 replies
Conference abstracts
4735Omatched by Proffered paper 1: Genitourinary tumour, renal and urothelial
Perioperative pembrolizumab (pembro) or placebo (pbo) + neoadjuvant cisplatin (cis) and gemcitabine (gem) in participants (pts) with muscle-invasive bladder cancer (MIBC): the double-blind, phase 3 KEYNOTE-866 study
https://esmocongress.esmo.orgSource: UroToday.com · x.com